» Articles » PMID: 38459381

Role of Hyperbaric Oxygen in Filler-Induced Vascular Occlusion

Overview
Specialty General Surgery
Date 2024 Mar 8
PMID 38459381
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: The rising incidence of filler-induced vascular complications in the context of aesthetic procedures necessitates a thorough assessment of therapeutic options. Hyperbaric oxygen therapy (HBOT) has emerged as a potential intervention for filler-induced vascular occlusion (FIVO), although optimal dosing and timing remain undefined.

Methods: This review explores the pathophysiology of FIVO and elucidates HBOT's multifaceted role in salvaging ischemic tissue. The physical and biochemical mechanisms of HBOT, including its vasodilatory, anti-spasmodic, and anti-inflammatory effects, are examined.

Results: HBOT serves as an adjunctive therapy in FIVO management, emphasizing timely intervention, adherence to specific pressures (two atmosphere absolute), and session durations (60 minutes) to optimize efficacy and minimize complications. While existing HBOT protocols for compromised grafts provide insights, standardized guidelines for FIVO are lacking.

Conclusion: HBOT enhances tissue oxygenation, modulates reactive oxygen species, and influences angiogenesis and hypoxia response. However, it does not replace key treatment protocols for filler vascular complications. Further research and standardized protocols are warranted to define HBOT's definitive role in mitigating filler-induced vascular complications. Level of Evidence IV This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .

Citing Articles

Hyperbaric Oxygen Promotes Chronic Wound Healing in Sprague-Dawley Rats by Inhibiting Pyroptosis.

Ma H, Wei X, Lin E, Wang Y, Huang J, Wei H Physiol Res. 2025; 73(6):1049-1061.

PMID: 39903894 PMC: 11835222.

References
1.
Soares MD D . Bridging a Century-Old Problem: The Pathophysiology and Molecular Mechanisms of HA Filler-Induced Vascular Occlusion (FIVO)-Implications for Therapeutic Interventions. Molecules. 2022; 27(17). PMC: 9458226. DOI: 10.3390/molecules27175398. View

2.
Mathieu D, Marroni A, Kot J . Tenth European Consensus Conference on Hyperbaric Medicine: recommendations for accepted and non-accepted clinical indications and practice of hyperbaric oxygen treatment. Diving Hyperb Med. 2017; 47(1):24-32. PMC: 6147240. DOI: 10.28920/dhm47.1.24-32. View

3.
de la Guardia C, Virno A, Musumeci M, Bernardin A, Silberberg M . Rheologic and Physicochemical Characteristics of Hyaluronic Acid Fillers: Overview and Relationship to Product Performance. Facial Plast Surg. 2022; 38(2):116-123. PMC: 9188840. DOI: 10.1055/s-0041-1741560. View

4.
Chiang C, Zhou S, Liu K . Intravenous Hyaluronidase with Urokinase as Treatment for Arterial Hyaluronic Acid Embolism. Plast Reconstr Surg. 2015; 137(1):114-121. DOI: 10.1097/PRS.0000000000001931. View

5.
de la Motte C, Nigro J, Vasanji A, Rho H, Kessler S, Bandyopadhyay S . Platelet-derived hyaluronidase 2 cleaves hyaluronan into fragments that trigger monocyte-mediated production of proinflammatory cytokines. Am J Pathol. 2009; 174(6):2254-64. PMC: 2684190. DOI: 10.2353/ajpath.2009.080831. View